{"id":"NCT00975286","sponsor":"Sanofi","briefTitle":"24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine","officialTitle":"A Randomized, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Double-blind Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine and Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2011-08","completion":"2011-08","firstPosted":"2009-09-11","resultsPosted":"2016-10-11","lastUpdate":"2016-10-11"},"enrollment":446,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Lixisenatide (AVE0010)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Insulin glargine","otherNames":["LantusÂ®"]},{"type":"DEVICE","name":"Pen auto-injector","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":[]},{"type":"DRUG","name":"Thiazolidinedione (TZD)","otherNames":[]}],"arms":[{"label":"Lixisenatide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to insulin glargine and metformin with or without thiazolidinediones (TZDs), over a period of 24 weeks of treatment.\n\nThe primary objective is to assess the effects of lixisenatide in comparison to placebo, when added to insulin glargine and metformin, on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 24.\n\nThe secondary objectives are to assess the effects of lixisenatide on the percentage of patients reaching HbA1c less than (\\<) 7 percent (%) and less than or equal to (\\<=) 6.5%, plasma glucose (fasting, postprandial during a standardized meal challenge test, 7-point self monitored profiles), body weight, insulin glargine doses, to evaluate safety and tolerability (including anti-lixisenatide antibody assessment), and to assess the impact on treatment satisfaction using the Diabetes Treatment Satisfaction Questionnaire (state) (DTSQs) in the participating countries where it is validated.","primaryOutcome":{"measure":"Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Placebo","deltaMin":-0.4,"sd":0.092},{"arm":"Lixisenatide","deltaMin":-0.71,"sd":0.091}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":25},"locations":{"siteCount":140,"countries":["United States","Argentina","Brazil","Canada","Chile","Colombia","Czechia","Denmark","Estonia","France","Germany","Hungary","India","Israel","Italy","Malaysia","Mexico","Netherlands","Poland","Puerto Rico","Romania","Russia","South Africa","Sweden","Taiwan","Ukraine"]},"refs":{"pmids":["23564915","36809495","31956422","29974618","25130920","23628617"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":223},"commonTop":["Hypoglycaemia","Nausea","Headache","Influenza","Vomiting"]}}